$STRM
STREAMLINE HEALTH SOLUTIONS INC. Stock $strm

$strm Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-K Financial Statement

#000149315224017297 Filed on April 30, 2024

Income Statement

Concept	2024 Q2	2024 Q1	2024
Revenue	$4.330M	$5.361M	$22.60M
YoY Change	-18.79%	-20.52%	-9.21%
Cost Of Revenue	$2.277M	$2.442M	$11.05M
YoY Change	-18.27%	-70.94%	-17.48%
Gross Profit	$2.053M	$2.919M	$11.54M
YoY Change	-19.36%	-275.95%	0.43%
Gross Profit Margin	47.41%	54.45%	51.08%
Selling, General & Admin	$3.192M	$2.631M	$14.71M
YoY Change	-16.13%	-27.84%	-8.83%
% of Gross Profit	155.48%	90.13%	127.44%
Research & Development	$1.111M	$1.394M	$5.704M
YoY Change	-34.69%	-7.99%	-5.59%
% of Gross Profit	54.12%	47.76%	49.42%
Depreciation & Amortization	$1.120M	$1.067M	$45.00K
YoY Change	5.76%	-75.03%	-16.67%
% of Gross Profit	54.55%	36.55%	0.39%
Operating Expenses	$4.303M	$4.025M	$20.41M
YoY Change	-21.86%	2281.66%	-7.95%
Operating Profit	-$2.250M	-$1.106M	-$19.65M
YoY Change	-24.9%	-39.5%	81.4%
Interest Expense	$465.0K	-$290.0K	$1.071M
YoY Change	87.5%	26.09%	42.99%
% of Operating Profit
Other Income/Expense, Net	$0.00	$39.00K	$31.00K
YoY Change	-100.0%	-22.0%	-84.58%
Pretax Income	-$2.739M	-$1.357M	-$18.74M
YoY Change	-3.83%	-36.38%	65.75%
Income Tax	$0.00	$13.00K	-$46.00K
% Of Pretax Income
Net Earnings	-$2.739M	-$1.370M	-$18.70M
YoY Change	-5.58%	-37.21%	64.31%
Net Earnings / Revenue	-63.26%	-25.55%	-82.74%
Basic Earnings Per Share	-$0.05		-$0.33
Diluted Earnings Per Share	-$0.05	-$0.02	-$0.33
COMMON SHARES
Basic Shares Outstanding	65.36M shares		56.51M shares
Diluted Shares Outstanding			56.51M shares

Balance Sheet

Concept	2024 Q2	2024 Q1	2024
SHORT-TERM ASSETS
Cash & Short-Term Investments	$3.979M	$3.190M	$3.190M
YoY Change	-33.54%	-51.65%	-51.65%
Cash & Equivalents	$3.979M	$3.190M	$3.190M
Short-Term Investments
Other Short-Term Assets	$722.0K	$629.0K	$629.0K
YoY Change	0.7%	-11.41%	-11.41%
Inventory
Prepaid Expenses
Receivables	$4.706M	$4.237M	$4.237M
Other Receivables	$294.0K	$780.0K	$780.0K
Total Short-Term Assets	$9.701M	$8.836M	$8.836M
YoY Change	-15.78%	-44.73%	-44.73%
LONG-TERM ASSETS
Property, Plant & Equipment	$76.00K	$88.00K	$88.00K
YoY Change	-23.23%	-20.72%	-20.72%
Goodwill	$13.28M	$13.28M
YoY Change	-42.5%	-42.5%
Intangibles	$11.66M	$12.07M
YoY Change	-18.69%	-18.4%
Long-Term Investments
YoY Change
Other Assets	$1.386M	$1.666M	$1.666M
YoY Change	-13.27%	-1.71%	-1.71%
Total Long-Term Assets	$32.02M	$32.90M	$32.90M
YoY Change	-28.78%	-27.75%	-27.75%
TOTAL ASSETS
Total Short-Term Assets	$9.701M	$8.836M	$8.836M
Total Long-Term Assets	$32.02M	$32.90M	$32.90M
Total Assets	$41.73M	$41.74M	$41.74M
YoY Change	-26.13%	-32.16%	-32.16%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.120M	$1.253M	$1.253M
YoY Change	274.58%	100.16%	100.16%
Accrued Expenses	$1.777M	$2.023M	$2.023M
YoY Change	-29.06%	-38.04%	-38.7%
Deferred Revenue	$7.351M	$7.112M
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.750M	$1.500M	$1.500M
YoY Change	100.0%	100.0%	100.0%
Total Short-Term Liabilities	$12.82M	$13.68M	$13.68M
YoY Change	-11.22%	-18.44%	-18.44%
LONG-TERM LIABILITIES
Long-Term Debt	$10.68M	$7.566M	$9.066M
YoY Change	22.12%	-15.6%	1.14%
Other Long-Term Liabilities	$931.0K		$173.0K
YoY Change	551.05%		-36.16%
Total Long-Term Liabilities	$11.61M	$9.239M	$9.239M
YoY Change	29.12%	0.04%	0.04%
TOTAL LIABILITIES
Total Short-Term Liabilities	$12.82M	$13.68M	$13.68M
Total Long-Term Liabilities	$11.61M	$9.239M	$9.239M
Total Liabilities	$24.42M	$22.92M	$22.92M
YoY Change	4.26%	-11.88%	-11.88%
SHAREHOLDERS EQUITY
Retained Earnings	-$118.4M	-$115.7M
YoY Change	18.55%	19.23%
Common Stock	$617.0K	$134.5M
YoY Change	-99.54%	1.48%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$17.30M	$18.81M	$18.81M
YoY Change
Total Liabilities & Shareholders Equity	$41.73M	$41.74M	$41.74M
YoY Change	-26.13%	-32.16%	-32.16%

Cashflow Statement

Concept	2024 Q2	2024 Q1	2024
OPERATING ACTIVITIES
Net Income	-$2.739M	-$1.370M	-$18.70M
YoY Change	-5.58%	-37.21%	64.31%
Depreciation, Depletion And Amortization	$1.120M	$1.067M	$45.00K
YoY Change	5.76%	-75.03%	-16.67%
Cash From Operating Activities	-$1.199M	-$54.00K	-$2.215M
YoY Change	-1051.59%	-97.77%	-68.99%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$12.00K	$54.00K
YoY Change	-100.0%	-97.55%	440.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$232.0K	-$12.00K	-$1.621M
YoY Change	-46.42%	-97.55%	-16.23%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change			-100.0%
Debt Paid & Issued, Net	$250.0K		$750.0K
YoY Change	100.0%		200.0%
Cash From Financing Activities	$2.220M	699.0K	$428.0K
YoY Change	-830.26%	-131.93%	-92.61%
NET CHANGE
Cash From Operating Activities	-$1.199M	-54.00K	-$2.215M
Cash From Investing Activities	-$232.0K	-12.00K	-$1.621M
Cash From Financing Activities	$2.220M	699.0K	$428.0K
Net Change In Cash	$789.0K	633.0K	-$3.408M
YoY Change	-229.13%	-112.41%	3.68%
FREE CASH FLOW
Cash From Operating Activities	-$1.199M	-$54.00K	-$2.215M
Capital Expenditures	$0.00	$12.00K	$54.00K
Free Cash Flow	-$1.199M	-$66.00K	-$2.269M
YoY Change	-1336.08%	-97.73%	-68.28%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024	dei	Amendment Flag AmendmentFlag	false
CY2024	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2024	dei	Entity Central Index Key EntityCentralIndexKey	0001008586
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset		usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent		usd
CY2023Q1	us-gaap	Long Term Line Of Credit LongTermLineOfCredit		usd
CY2024Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent		usd
CY2024Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss		usd
CY2023	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse		usd
CY2023	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
CY2023	us-gaap	Stock Issued During Period Value Restricted Stock Award Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures		usd
CY2024	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
CY2024	us-gaap	Stock Issued During Period Value Restricted Stock Award Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures		usd
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss		usd
CY2023	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse		usd
CY2024	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2024	us-gaap	Payments Of Merger Related Costs Financing Activities PaymentsOfMergerRelatedCostsFinancingActivities		usd
CY2024	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts		usd
CY2023	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit		usd
CY2024	us-gaap	Restricted Stock Expense RestrictedStockExpense		usd
CY2023	STRM	Deferred Financing Costs DeferredFinancingCosts		usd
CY2024	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs		usd
CY2024	STRM	Effect Of Dilutive Securities Stock Options Restricted Stocks EffectOfDilutiveSecuritiesStockOptionsRestrictedStocks		shares
CY2023	STRM	Effect Of Dilutive Securities Stock Options Restricted Stocks EffectOfDilutiveSecuritiesStockOptionsRestrictedStocks		shares
CY2024	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2024Q1	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssets		usd
CY2024Q1	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities		usd
CY2024	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions		usd
CY2023	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations		usd
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
CY2024	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2024	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue		usd
CY2024	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions		usd
CY2023	us-gaap	Valuation Allowances And Reserves Charged To Other Accounts ValuationAllowancesAndReservesChargedToOtherAccounts		usd
CY2024	dei	Document Type DocumentType	10-K
CY2024	dei	Document Annual Report DocumentAnnualReport	true
CY2024	dei	Document Period End Date DocumentPeriodEndDate	2024-01-31
CY2024	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--01-31
CY2024	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024	dei	Document Transition Report DocumentTransitionReport	false
CY2024	dei	Entity File Number EntityFileNumber	000-28132
CY2024	dei	Entity Registrant Name EntityRegistrantName	STREAMLINE HEALTH SOLUTIONS, INC.
CY2024	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2024	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	31-1455414
CY2024	dei	Entity Address Address Line1 EntityAddressAddressLine1	2400 Old Milton Pkwy.
CY2024	dei	Entity Address Address Line2 EntityAddressAddressLine2	Box 1353
CY2024	dei	Entity Address City Or Town EntityAddressCityOrTown	Alpharetta
CY2024	dei	Entity Address State Or Province EntityAddressStateOrProvince	GA
CY2024	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	30009
CY2024	dei	City Area Code CityAreaCode	(888)
CY2024	dei	Local Phone Number LocalPhoneNumber	997-8732
CY2024	dei	Security12b Title Security12bTitle	Common Stock, $0.01 par value per share
CY2024	dei	Trading Symbol TradingSymbol	STRM
CY2024	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2024	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2024	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	750000	usd
CY2024	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024	dei	Entity Small Business EntitySmallBusiness	true
CY2024	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2024	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2024	dei	Entity Shell Company EntityShellCompany	false
CY2023Q3	dei	Entity Public Float EntityPublicFloat	57165443	usd
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	65362533	shares
CY2024	dei	Auditor Name AuditorName	FORVIS, LLP
CY2024	dei	Auditor Location AuditorLocation	Atlanta, Georgia
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3190000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6598000	usd
CY2024Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	86000	usd
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	132000	usd
CY2024Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4237000	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	7719000	usd
CY2024Q1	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	780000	usd
CY2023Q1	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	960000	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	629000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	710000	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	8836000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	15987000	usd
CY2024Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	291000	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	246000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	88000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	79000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	32000	usd
CY2024Q1	us-gaap	Capitalized Computer Software Accumulated Amortization CapitalizedComputerSoftwareAccumulatedAmortization	7960000	usd
CY2023Q1	us-gaap	Capitalized Computer Software Accumulated Amortization CapitalizedComputerSoftwareAccumulatedAmortization	6224000	usd
CY2024Q1	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	5798000	usd
CY2023Q1	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	5846000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	4019000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	2627000	usd
CY2024Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	12071000	usd
CY2023Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	14793000	usd
CY2024Q1	us-gaap	Goodwill Goodwill	13276000	usd
CY2023Q1	us-gaap	Goodwill Goodwill	23089000	usd
CY2024Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1666000	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1695000	usd
CY2024Q1	us-gaap	Assets Noncurrent AssetsNoncurrent	32899000	usd
CY2023Q1	us-gaap	Assets Noncurrent AssetsNoncurrent	45534000	usd
CY2024Q1	us-gaap	Assets Assets	41735000	usd
CY2023Q1	us-gaap	Assets Assets	61521000	usd
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	1253000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	626000	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2023000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3265000	usd
CY2024Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	1500000	usd
CY2024Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	7112000	usd
CY2023Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	8361000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	35000	usd
CY2024Q1	us-gaap	Asset Acquisition Contingent Consideration Liability Current AssetAcquisitionContingentConsiderationLiabilityCurrent	1794000	usd
CY2023Q1	us-gaap	Asset Acquisition Contingent Consideration Liability Current AssetAcquisitionContingentConsiderationLiabilityCurrent	3738000	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	13682000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	16775000	usd
CY2024Q1	us-gaap	Long Term Loans Payable LongTermLoansPayable	7566000	usd
CY2023Q1	us-gaap	Long Term Loans Payable LongTermLoansPayable	8964000	usd
CY2024Q1	us-gaap	Long Term Line Of Credit LongTermLineOfCredit	1500000	usd
CY2024Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	173000	usd
CY2023Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	167000	usd
CY2023Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	104000	usd
CY2024Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	9239000	usd
CY2023Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	9235000	usd
CY2024Q1	us-gaap	Liabilities Liabilities	22921000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	26010000	usd
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	85000000	shares
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	85000000	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	58945498	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	58945498	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	57567210	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	57567210	shares
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	590000	usd
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	576000	usd
CY2024Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	133923000	usd
CY2023Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	131973000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-115699000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-97038000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	18814000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	35511000	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	41735000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	61521000	usd
CY2024	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	22596000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	24889000	usd
CY2024	STRM	Cost Of Software As Service CostOfSoftwareAsService	6573000	usd
CY2023	STRM	Cost Of Software As Service CostOfSoftwareAsService	6358000	usd
CY2024	STRM	Cost Of Maintenance And Support CostOfMaintenanceAndSupport	315000	usd
CY2023	STRM	Cost Of Maintenance And Support CostOfMaintenanceAndSupport	427000	usd
CY2024	STRM	Cost Of Professional Fees And Licenses CostOfProfessionalFeesAndLicenses	4165000	usd
CY2023	STRM	Cost Of Professional Fees And Licenses CostOfProfessionalFeesAndLicenses	6610000	usd
CY2024	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	14710000	usd
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	16283000	usd
CY2024	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5704000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6042000	usd
CY2024	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	9813000	usd
CY2024	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	963000	usd
CY2024	us-gaap	Costs And Expenses CostsAndExpenses	42243000	usd
CY2023	us-gaap	Costs And Expenses CostsAndExpenses	35720000	usd
CY2024	us-gaap	Operating Income Loss OperatingIncomeLoss	-19647000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-10831000	usd
CY2024	us-gaap	Interest Expense InterestExpense	1071000	usd
CY2023	us-gaap	Interest Expense InterestExpense	749000	usd
CY2024	STRM	Acquisition Earnout Valuation Adjustments AcquisitionEarnoutValuationAdjustments	1944000	usd
CY2023	STRM	Acquisition Earnout Valuation Adjustments AcquisitionEarnoutValuationAdjustments	71000	usd
CY2024	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	31000	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	201000	usd
CY2024	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-18743000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-11308000	usd
CY2024	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-46000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	71000	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-18697000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-11379000	usd
CY2024	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.33
CY2024	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.33
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.23
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.23
CY2024	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	56510419	shares
CY2024	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	56510419	shares
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	49324858	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	49324858	shares
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	34044000	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	6000	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	11328000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	-52000	usd
CY2023	STRM	Stock Issued During Period Value Surrender Of Shares StockIssuedDuringPeriodValueSurrenderOfShares	-197000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1761000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-11379000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	35511000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	35511000	usd
CY2024	STRM	Stock Issued During Period Value Surrender Of Shares StockIssuedDuringPeriodValueSurrenderOfShares	-280000	usd
CY2024	us-gaap	Stockholders Equity Other StockholdersEquityOther	36000	usd
CY2024	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	2244000	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-18697000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	18814000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	18814000	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-18697000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-11379000	usd
CY2024	us-gaap	Depreciation And Amortization DepreciationAndAmortization	4331000	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	4313000	usd
CY2024	STRM	Acquisition Earnout Valuation Adjustments AcquisitionEarnoutValuationAdjustments	1944000	usd
CY2023	STRM	Acquisition Earnout Valuation Adjustments AcquisitionEarnoutValuationAdjustments	71000	usd
CY2024	STRM	Provision For Deferred Income Taxes ProvisionForDeferredIncomeTaxes	-104000	usd
CY2023	STRM	Provision For Deferred Income Taxes ProvisionForDeferredIncomeTaxes	9000	usd
CY2024	us-gaap	Share Based Compensation ShareBasedCompensation	2102000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	1680000	usd
CY2024	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	9813000	usd
CY2024	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	963000	usd
CY2024	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-10000	usd
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	189000	usd
CY2024	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-3708000	usd
CY2023	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	4202000	usd
CY2024	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	401000	usd
CY2023	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	1197000	usd
CY2024	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	544000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-152000	usd
CY2024	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1277000	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1069000	usd
CY2024	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-1243000	usd
CY2023	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	2598000	usd
CY2024	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2215000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7143000	usd
CY2024	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	54000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	10000	usd
CY2024	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware	1567000	usd
CY2023	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware	1925000	usd
CY2024	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1621000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1935000	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	8316000	usd
CY2023	us-gaap	Payments Of Merger Related Costs Financing Activities PaymentsOfMergerRelatedCostsFinancingActivities	2012000	usd
CY2023	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	52000	usd
CY2024	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	750000	usd
CY2023	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	250000	usd
CY2024	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	1500000	usd
CY2024	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	280000	usd
CY2023	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	197000	usd
CY2024	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	44000	usd
CY2023	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	20000	usd
CY2024	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	2000	usd
CY2023	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	6000	usd
CY2024	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	428000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5791000	usd
CY2024	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3408000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3287000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	6598000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	9885000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3190000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	6598000	usd
CY2024	us-gaap	Interest Paid Net InterestPaidNet	989000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	651000	usd
CY2024	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	66000	usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	23000	usd
CY2024	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_84D_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zT18YACMCUE2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_zLdYdGtUBpJ7">Reclassification</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain amounts for fiscal 2022 were reclassified to conform to the current period classification. The Company incurred certain acquisition-related costs related to the acquisition of Avelead totaling $<span id="xdx_90C_eus-gaap--BusinessCombinationAcquisitionRelatedCosts_c20230201__20240131_zLSxskQwCZpi" title="Acquisition related costs">149,000</span> consisting primarily of professional service fees. The aforementioned acquisition-related costs for fiscal 2022 were previously presented in a separate, single caption and are now included in selling, general, and administrative expense in the accompanying condensed consolidated statements of operations, which is consistent with the presentation for the current period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	149000	usd
CY2024	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_841_eus-gaap--UseOfEstimates_zYRzg40CSL39" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_z7lvcZppkJTa">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates and judgments, including those related to the recognition of revenue, stock-based compensation, capitalization of software development costs, intangible assets, the allowance for credit losses, contingent consideration and income taxes. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023	us-gaap	Restricted Stock Expense RestrictedStockExpense	3012000	usd
CY2024	STRM	Capitalized Software Purchased With Stock CapitalizedSoftwarePurchasedWithStock	140000	usd
CY2023	STRM	Capitalized Software Purchased With Stock CapitalizedSoftwarePurchasedWithStock	81000	usd
CY2024	STRM	Deferred Financing Costs DeferredFinancingCosts	83000	usd
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	132000	usd
CY2024	STRM	Allowance For Doubtful Accounts Receivable Cecl Adoption AllowanceForDoubtfulAccountsReceivableCECLAdoption	-36000	usd
CY2024	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-10000	usd
CY2024Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	86000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-11379000	usd
CY2024	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	56510419	shares
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	49324858	shares
CY2024Q1	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1071000	usd
CY2023Q1	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	2079000	usd
CY2024Q1	us-gaap	Accrued Exchange Fee Rebate Current And Noncurrent AccruedExchangeFeeRebateCurrentAndNoncurrent	389000	usd
CY2023Q1	us-gaap	Accrued Exchange Fee Rebate Current And Noncurrent AccruedExchangeFeeRebateCurrentAndNoncurrent	294000	usd
CY2024Q1	STRM	Third Partylicense ThirdPartylicense	43000	usd
CY2023Q1	STRM	Third Partylicense ThirdPartylicense	285000	usd
CY2024Q1	STRM	Concession Accrual Amount ConcessionAccrualAmount	233000	usd
CY2023Q1	STRM	Concession Accrual Amount ConcessionAccrualAmount	226000	usd
CY2024Q1	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	226000	usd
CY2023Q1	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	331000	usd
CY2024Q1	us-gaap	Interest Payable Current InterestPayableCurrent	61000	usd
CY2023Q1	us-gaap	Interest Payable Current InterestPayableCurrent	50000	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2023000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3265000	usd
CY2024Q1	STRM	Concession Accrual Amount ConcessionAccrualAmount	233000	usd
CY2023Q1	STRM	Concession Accrual Amount ConcessionAccrualAmount	226000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6042000	usd
CY2024Q1	STRM	Acquisition Earnout Liability Fair Value AcquisitionEarnoutLiabilityFairValue	1794000	usd
CY2023Q1	STRM	Acquisition Earnout Liability Fair Value AcquisitionEarnoutLiabilityFairValue	3738000	usd
CY2024	STRM	Acquisition Earnout Liability Change In Valuation AcquisitionEarnoutLiabilityChangeInValuation	1944000	usd
CY2024Q1	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.015	pure
CY2024	us-gaap	Depreciation Depreciation	45000	usd
CY2023	us-gaap	Depreciation Depreciation	54000	usd
CY2024	us-gaap	Asset Impairment Charges AssetImpairmentCharges	18000	usd
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2024	STRM	Amortized And Abandoned Assets AmortizedAndAbandonedAssets	18000	usd
CY2024	us-gaap	Capitalized Computer Software Amortization1 CapitalizedComputerSoftwareAmortization1	2463000	usd
CY2023	us-gaap	Capitalized Computer Software Amortization1 CapitalizedComputerSoftwareAmortization1	2423000	usd
CY2024	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5704000	usd
CY2024	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	22596000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	24889000	usd
CY2023Q1	us-gaap	Deferred Revenue DeferredRevenue	7642000	usd
CY2024Q1	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	31414000	usd
CY2024	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Explanation RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation	the Company expects to recognize approximately 46% over the next 12 months and the remainder thereafter.
CY2024Q1	us-gaap	Deferred Costs Current And Noncurrent DeferredCostsCurrentAndNoncurrent	77000	usd
CY2023Q1	us-gaap	Deferred Costs Current And Noncurrent DeferredCostsCurrentAndNoncurrent	94000	usd
CY2024Q1	us-gaap	Accumulated Amortization Of Other Deferred Costs AccumulatedAmortizationOfOtherDeferredCosts	102000	usd
CY2023Q1	us-gaap	Accumulated Amortization Of Other Deferred Costs AccumulatedAmortizationOfOtherDeferredCosts	176000	usd
CY2024	STRM	Deferred Costs Amortization Expenses DeferredCostsAmortizationExpenses	82000	usd
CY2023	STRM	Deferred Costs Amortization Expenses DeferredCostsAmortizationExpenses	83000	usd
CY2024	us-gaap	Other Amortization Of Deferred Charges OtherAmortizationOfDeferredCharges	155000	usd
CY2024	us-gaap	Capitalized Contract Cost Impairment Loss CapitalizedContractCostImpairmentLoss	35000	usd
CY2023	us-gaap	Capitalized Contract Cost Impairment Loss CapitalizedContractCostImpairmentLoss	0	usd
CY2024	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_844_eus-gaap--ConcentrationRiskCreditRisk_zL8F4xbnR08b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zXy7zlnS4U5c">Concentrations</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments, which potentially expose the Company to concentrations of credit risk, consist primarily of accounts receivable. The Company’s accounts receivables are concentrated in the healthcare industry. However, the Company’s clients typically are well-established hospitals, medical facilities or major health information systems companies with good credit histories that resell the Company’s solutions. Payments from clients have been received within normal time frames for the industry. However, some hospitals and medical facilities have experienced significant operating losses as a result of limits on third-party reimbursements from insurance companies and governmental entities and extended payment of receivables from these entities is not uncommon.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To date, the Company has relied on a limited number of clients and remarketing partners for a substantial portion of its total revenues. The Company expects that a significant portion of its future revenues will continue to be generated by a limited number of clients and its remarketing partners. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>
CY2024	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-18697000	usd
CY2023	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-11379000	usd
CY2024	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.33
CY2023	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.23
CY2024	us-gaap	Net Income Loss From Continuing Operations Available To Common Shareholders Diluted NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted	-18697000	usd
CY2023	us-gaap	Net Income Loss From Continuing Operations Available To Common Shareholders Diluted NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted	-11379000	usd
CY2024	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.33
CY2023	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.23
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-18697000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	16090000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	4019000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	12071000	usd
CY2024	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	56510419	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	49324858	shares
CY2024	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.33
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.33
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.33
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.23
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.23
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.23
CY2023Q4	STRM	Number Of Employees Terminated NumberOfEmployeesTerminated	26	integer
CY2023Q4	STRM	Percentage Of Workforce Terminated PercentageOfWorkforceTerminated	0.24	pure
CY2023Q4	us-gaap	Restructuring Costs RestructuringCosts	759000	usd
CY2024Q1	us-gaap	Rental Properties RentalProperties	30000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	540000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	32000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	35000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.065	pure
CY2024	us-gaap	Operating Lease Cost OperatingLeaseCost	32000	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	194000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	17420000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	2627000	usd
CY2024Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	9000000	usd
CY2023Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	9750000	usd
CY2024Q1	STRM	Financing Cost Payable FinancingCostPayable	135000	usd
CY2023Q1	STRM	Financing Cost Payable FinancingCostPayable	69000	usd
CY2024Q1	STRM	Deferred Financing Cost DeferredFinancingCost	69000	usd
CY2023Q1	STRM	Deferred Financing Cost DeferredFinancingCost	105000	usd
CY2024Q1	us-gaap	Long Term Debt LongTermDebt	9066000	usd
CY2023Q1	us-gaap	Long Term Debt LongTermDebt	9714000	usd
CY2024Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	1500000	usd
CY2023Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	750000	usd
CY2024Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	7566000	usd
CY2023Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	8964000	usd
CY2024Q1	us-gaap	Long Term Line Of Credit LongTermLineOfCredit	1500000	usd
CY2023Q1	us-gaap	Goodwill Goodwill	23089000	usd
CY2024	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	9813000	usd
CY2024Q1	us-gaap	Goodwill Goodwill	13276000	usd
CY2024	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	9813000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	14793000	usd
CY2024	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1760000	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1971000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Rolling Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths	1635000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	1635000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	1635000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	1635000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	1635000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	3896000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	12071000	usd
CY2024	STRM	Abandoned Asset Wrote Off AbandonedAssetWroteOff	1330000	usd
CY2024	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	-58000	usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	-62000	usd
CY2024	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-58000	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-62000	usd
CY2024	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	86000	usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-6000	usd
CY2024	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	18000	usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-3000	usd
CY2024	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	104000	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-9000	usd
CY2024	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-46000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	71000	usd
CY2024	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2024	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	3887000	usd
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	2348000	usd
CY2024	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-28000	usd
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-52000	usd
CY2024	STRM	Increase In Valuation Allowance IncreaseInValuationAllowance	-3994000	usd
CY2023	STRM	Increase In Valuation Allowance IncreaseInValuationAllowance	-2128000	usd
CY2024	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	-36000	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	-20000	usd
CY2024	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	-7000	usd
CY2023	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	-18000	usd
CY2024	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	-33000	usd
CY2023	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	-91000	usd
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	135000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	-289000	usd
CY2024	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	56000	usd
CY2023	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-3000	usd
CY2024	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-46000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	71000	usd
CY2024Q1	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	26000	usd
CY2023Q1	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	39000	usd
CY2024Q1	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	209000	usd
CY2023Q1	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	122000	usd
CY2024Q1	STRM	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities Current DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesCurrent	67000	usd
CY2023Q1	STRM	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities Current DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesCurrent	232000	usd
CY2024Q1	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	15748000	usd
CY2023Q1	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	11242000	usd
CY2024Q1	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	427000	usd
CY2023Q1	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	342000	usd
CY2024Q1	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	1739000	usd
CY2023Q1	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	1344000	usd
CY2024Q1	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	1434000	usd
CY2023Q1	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	1407000	usd
CY2024Q1	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1000	usd
CY2023Q1	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	2000	usd
CY2024Q1	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	19651000	usd
CY2023Q1	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	14730000	usd
CY2024Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	19646000	usd
CY2023Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	14347000	usd
CY2024Q1	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	5000	usd
CY2023Q1	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	383000	usd
CY2024Q1	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	5000	usd
CY2023Q1	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	5000	usd
CY2023Q1	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssets	482000	usd
CY2024Q1	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	5000	usd
CY2023Q1	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	487000	usd
CY2023Q1	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	104000	usd
CY2024Q1	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	65107000	usd
CY2024Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	19646000	usd
CY2023Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	14347000	usd
CY2024	STRM	Increase In Valuation Allowance IncreaseInValuationAllowance	-3994000	usd
CY2024Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	340000	usd
CY2023Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	333000	usd
CY2023Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	333000	usd
CY2022Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	315000	usd
CY2024	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	9000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	11000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	7000	usd
CY2024	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	2000	usd
CY2024Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	340000	usd
CY2023Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	333000	usd
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	65000000	shares
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	85000000	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	1000000	shares
CY2024	us-gaap	Concentration Risk Customer ConcentrationRiskCustomer	one individual client accounted for 10% or more of our revenue.
CY2023	us-gaap	Concentration Risk Customer ConcentrationRiskCustomer	two individual clients accounted for 10% or more of our revenue.
CY2024	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	242000	usd
CY2023	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	258000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	628958	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.95
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y3M21D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	360000	usd
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	39250	shares
CY2024	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	7.14
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	522208	shares
CY2024	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	1.55
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	67500	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.73
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P2Y4M13D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	67500	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1.73
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P2Y4M13D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	67500	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	1.73
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P2Y4M13D
CY2024Q1	STRM	Investment Ownership Percentage InvestmentOwnershipPercentage	0.20	pure
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	1043350	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	1.57
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	1848031	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	1.48
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	1970521	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	1.51
CY2024	us-gaap	Payments For Rent PaymentsForRent	6000	usd
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	132000	usd
CY2024	us-gaap	Valuation Allowances And Reserves Charged To Cost And Expense ValuationAllowancesAndReservesChargedToCostAndExpense	-10000	usd
CY2024	us-gaap	Valuation Allowances And Reserves Charged To Other Accounts ValuationAllowancesAndReservesChargedToOtherAccounts	-36000	usd
CY2024Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	86000	usd
CY2022Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	76000	usd
CY2023	us-gaap	Valuation Allowances And Reserves Charged To Cost And Expense ValuationAllowancesAndReservesChargedToCostAndExpense	189000	usd
CY2023	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	-133000	usd
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	132000	usd
CY2024	dei	Auditor Firm AuditorFirmId	686

Files In Submission

Name	View Source	Status
0001493152-24-017297-index-headers.html	Edgar Link	pending
0001493152-24-017297-index.html	Edgar Link	pending
0001493152-24-017297.txt	Edgar Link	pending
0001493152-24-017297-xbrl.zip	Edgar Link	pending
ex10-5.htm	Edgar Link	pending
ex10-7.htm	Edgar Link	pending
ex21-1.htm	Edgar Link	pending
ex23-1.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
ex4-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
form10-k_htm.xml	Edgar Link	completed
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
strm-20240131.xsd	Edgar Link	pending
strm-20240131_def.xml	Edgar Link	unprocessable
strm-20240131_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
strm-20240131_cal.xml	Edgar Link	unprocessable
strm-20240131_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$STRM
STREAMLINE HEALTH SOLUTIONS INC. Stock $strm

2024 Q2 Form 10-K Financial Statement

#000149315224017297 Filed on April 30, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$STRM STREAMLINE HEALTH SOLUTIONS INC. Stock $strm

2024 Q2 Form 10-K Financial Statement

#000149315224017297 Filed on April 30, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$STRM
STREAMLINE HEALTH SOLUTIONS INC. Stock $strm